# ClinicalTrials.gov record NCT03884075

> PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03884075-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-10
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03884075-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03884075-semaglutide-v1.json
- Content SHA-256: `f3ec6cdb7d9e6a96f35b837745e872ccbdb62de42e440236bf28723d1a502013`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03884075 ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

## Sources

<a id="source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b"></a>
- **ClinicalTrials.gov record NCT03884075 · retained source version 2026-08-10:96efb931ce5b056903aeedaabc69b04f7b6dd18707021615d0c48d10797bedae** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03884075) (`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03884075." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03884075-semaglutide-v1.json SHA-256: f3ec6cdb7d9e6a96f35b837745e872ccbdb62de42e440236bf28723d1a502013.